Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT151 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**BNT151 + pembrolizumab** is an investigational combination therapy for patients with advanced solid tumors. BNT151 is a mRNA-based immunotherapy that encodes interleukin-2 (IL-2) designed to stimulate anti-tumor immune responses, while pembrolizumab is a monoclonal antibody that blocks the PD-1 immune checkpoint receptor, enhancing T-cell mediated antitumor activity. The combination aims to synergize enhanced immune activation (via IL-2) and immune checkpoint inhibition (via PD-1 blockade). Clinical trials are investigating this combination for various advanced or metastatic solid tumors, including squamous cell carcinoma of the head and neck, hepatocellular carcinoma, renal cell carcinoma, non-small cell lung cancer, and triple-negative breast cancer[1][2][5][7].
- Other names
- BNT151 + pembrolizumabBNT151-01 combinationBNT-151-01 combinationBNT 151-01 combination
02
Targets
IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BNT151 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT151 + pembrolizumab.